Cordlife (SGX:P8A) provided clarifications over certain media reports regarding its cord blood banking service license matters, according to a Tuesday filing with the Singapore Exchange.
Regarding a release made by the Ministry of Health, the company said that while 160 cord blood units were collected since January this year and the ministry did not state that all were affected by process failures.
Meanwhile, the company said that while it had been granted an extension of time by the MOH from Oct. 13 to submit written representations to avoid its license getting suspended, suspension will be under consideration based on representations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.